Related Experiment Video
Updated: May 15, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
CYP-mediated pharmacologic interference with optimal platelet inhibition.
Thomas Cuisset1, Jacques Quilici
1Département de Cardiologie, CHU Timone, Marseille F-13385, France. thomas.cuisset@ap-hm.fr
Journal of Cardiovascular Translational Research
|January 15, 2013
Summary
Drug interactions can affect how well clopidogrel and prasugrel work, impacting platelet inhibition. This review examines evidence on how drug interactions interfere with thienopyridine treatment effectiveness.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Cardiovascular Medicine
Background:
- Variability in patient response to thienopyridine antiplatelet agents like clopidogrel and prasugrel has clinical significance.
- Drug-drug interactions are suspected contributors to this response variability.
- Previous studies suggest biological modulation of clopidogrel response by drugs like atorvastatin and omeprazole, but clinical relevance remains debated.
Purpose of the Study:
- To review and summarize the scientific evidence regarding CYP-mediated drug interactions.
- To assess the impact of these interactions on optimal platelet inhibition in patients receiving thienopyridine therapy.
Main Methods:
- Literature review of existing scientific evidence.
- Analysis of studies investigating pharmacologic interference with P2Y12 inhibitors.
Main Results:
- Biological modulation of clopidogrel response by certain drugs has been observed.
- The clinical relevance and impact of these drug interactions on patient outcomes are still under investigation and considered debatable.
- For newer agents like prasugrel, response variability is lower, and drug interactions are less significant, not requiring dose adjustments.
Conclusions:
- CYP-mediated drug interactions can interfere with the effectiveness of thienopyridine antiplatelet therapy.
- Further research is needed to clarify the clinical impact of these interactions, especially for clopidogrel.
- Prasugrel appears less susceptible to clinically significant drug interactions affecting platelet inhibition.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...